GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (GREY:IFTBF) » Definitions » Receipts from Customers

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Receipts from Customers


View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Receipts from Customers?

Receipts from Customers only applicable to companies reporting Cash Flow from Operations in direct method.


Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Business Description

Traded in Other Exchanges
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Infant Bacterial Therapeutics AB is a pharmaceutical company that develops drugs influencing the human infant microbiome, and thereby prevents or treats rare diseases affecting premature infants. It is currently developing its lead drug candidate IBP-9414, to prevent NEC and improve feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants.